T2 Biosystems Initiates Studies to Add Acinetobacter Baumannii to the FDA-Cleared T2Bacteria Panel
October 20, 2022 09:05 ET
|
T2 Biosystems, Inc.
LEXINGTON, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today...
T2 Biosystems Highlights Multiple New Studies Demonstrating Improved Rapid Detection Across Several Patient Populations
October 14, 2022 08:30 ET
|
T2 Biosystems, Inc.
LEXINGTON, Mass., Oct. 14, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today...
T2 Biosystems Announces Plan to Commercialize a Diagnostic Test for Early Lyme Disease
October 13, 2022 09:00 ET
|
T2 Biosystems, Inc.
LEXINGTON, Mass., Oct. 13, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today...
T2 Biosystems Announces Preliminary Third Quarter 2022 Financial Results and Updates 2022 Financial Outlook
October 12, 2022 08:35 ET
|
T2 Biosystems, Inc.
LEXINGTON, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes,...
T2 Biosystems Announces Reverse Stock Split Effective Today
October 12, 2022 08:30 ET
|
T2 Biosystems, Inc.
LEXINGTON, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes,...
T2 Biosystems Announces BARDA Exercise of Contract Option 3 Valued at $3.7 Million
September 29, 2022 08:30 ET
|
T2 Biosystems, Inc.
LEXINGTON, Mass., Sept. 29, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today...
T2 Biosystems Announces Commercial Expansion Through Distributor in Baltic Region
September 22, 2022 16:05 ET
|
T2 Biosystems, Inc.
LEXINGTON, Mass., Sept. 22, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistant genes, today announced...
T2 Biosystems to Participate in the H.C. Wainwright Global Investment Conference
September 08, 2022 16:05 ET
|
T2 Biosystems, Inc.
LEXINGTON, Mass., Sept. 08, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced...
T2 Biosystems to Present at the Inaugural Gilmartin Group Emerging Growth Company Showcase
August 18, 2022 16:05 ET
|
T2 Biosystems, Inc.
LEXINGTON, Mass., Aug. 18, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced...
T2 Biosystems Announces Second Quarter 2022 Financial Results
August 15, 2022 16:05 ET
|
T2 Biosystems, Inc.
LEXINGTON, Mass., Aug. 15, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes,...